{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:21:27Z","timestamp":1781180487125,"version":"3.54.1"},"reference-count":30,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T00:00:00Z","timestamp":1353024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (<jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>) in phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials, these results are yet to be repeated in phase <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the treatment response to rifaximin in <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> patients in a phase <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> patients underwent lactulose hydrogen breath testing (<jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content>\u2010positive patients were treated with rifaximin for 14\u00a0days. Prior to treatment as well as at week 4 and 14 following the start of rifaximin treatment, patients completed a questionnaire assessing symptom severity on a Likert scale from 0 to 10.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and six of 150 <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> patients (71%) were <jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content>\u2010positive and treated with rifaximin. As assessed at week 4 following commencement of the therapy, rifaximin provided significant improvement of the following <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010associated symptoms: bloating (5.5\u00b12.6 before the start of the treatment vs. 3.6\u00b12.7 at week 4, <jats:italic>P<\/jats:italic>&lt;0.001), flatulence (5.0\u00b12.7 vs. 4.0\u00b12.7, <jats:italic>P<\/jats:italic>=0.015), diarrhoea (2.9\u00b12.4 vs. 2.0\u00b12.4, <jats:italic>P<\/jats:italic>=0.005) and abdominal pain (4.8\u00b12.7 vs. 3.3\u00b12.5, <jats:italic>P<\/jats:italic>&lt;0.001). Overall well\u2010being also significantly improved (3.9\u00a0\u00b1\u00a02.4 vs. 2.7\u00a0\u00b1\u00a02.3, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Similar improvements in <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> symptoms were obtained at week 14. Eighty\u2010six per cent of patients undergoing repetitive <jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content> (55\/64) tested negative at week 4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We found a high percentage of <jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content>\u2010positive <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> patients. <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010associated symptoms (bloating, flatulence, diarrhoea, pain) were improved for a period of 3\u00a0months following 2 weeks of treatment with rifaximin. We conclude that rifaximin treatment alleviates symptoms in <jats:styled-content style=\"fixed-case\">LHBT<\/jats:styled-content>\u2010positive <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12087","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T11:02:16Z","timestamp":1350385336000},"page":"1084-1093","source":"Crossref","is-referenced-by-count":47,"title":["Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3\u00a0months"],"prefix":"10.1111","volume":"36","author":[{"given":"P.","family":"Meyrat","sequence":"first","affiliation":[{"name":"Private Practice for Gastroenterology and Hepatology Solothurn Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Safroneeva","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine University of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Schoepfer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Centre Hospitalier Universitaire Vaudois\/CHUV Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01217.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01437.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01456.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624010-00002"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00157-6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.108712"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.031"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-0065-1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.678"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1276-4"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90818-L"},{"key":"e_1_2_6_14_1","first-page":"1795","article-title":"The lactulose hydrogen breath test and small intestinal bacterial overgrowth","volume":"91","author":"Riordan SM","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03368.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70336-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.019"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004409"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.355"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02493.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00458.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.671"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2313"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.14.1733"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01992.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.12.022"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.4"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1601651"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00574.2004"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.205476"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12087","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:32:28Z","timestamp":1697373148000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,16]]},"references-count":30,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/apt.12087"],"URL":"https:\/\/doi.org\/10.1111\/apt.12087","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,16]]}}}